Cargando…
PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043830/ http://dx.doi.org/10.1186/1546-0096-11-S2-P51 |
| _version_ | 1782319000517083136 |
|---|---|
| author | Mihailova, D Varbanova, B Stefanov, S Teltcharova, A |
| author_facet | Mihailova, D Varbanova, B Stefanov, S Teltcharova, A |
| author_sort | Mihailova, D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4043830 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-40438302014-06-17 PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA Mihailova, D Varbanova, B Stefanov, S Teltcharova, A Pediatr Rheumatol Online J Poster Presentation BioMed Central 2013-12-05 /pmc/articles/PMC4043830/ http://dx.doi.org/10.1186/1546-0096-11-S2-P51 Text en Copyright © 2013 Mihailova et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Mihailova, D Varbanova, B Stefanov, S Teltcharova, A PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA |
| title | PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA |
| title_full | PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA |
| title_fullStr | PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA |
| title_full_unstemmed | PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA |
| title_short | PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA |
| title_sort | pres-final-2038: clinical efficacy and tolerability of tocilizumab in patients with persistant systemic jia |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043830/ http://dx.doi.org/10.1186/1546-0096-11-S2-P51 |
| work_keys_str_mv | AT mihailovad presfinal2038clinicalefficacyandtolerabilityoftocilizumabinpatientswithpersistantsystemicjia AT varbanovab presfinal2038clinicalefficacyandtolerabilityoftocilizumabinpatientswithpersistantsystemicjia AT stefanovs presfinal2038clinicalefficacyandtolerabilityoftocilizumabinpatientswithpersistantsystemicjia AT teltcharovaa presfinal2038clinicalefficacyandtolerabilityoftocilizumabinpatientswithpersistantsystemicjia |